Barclays Reiterates “Underweight” Rating for Definitive Healthcare (NASDAQ:DH)

Definitive Healthcare (NASDAQ:DH)‘s stock had its “underweight” rating reaffirmed by Barclays in a research note issued on Monday, Marketbeat reports. They presently have a $4.00 target price on the stock. Barclays‘s price target would indicate a potential downside of 5.21% from the stock’s current price.

A number of other research firms have also recently weighed in on DH. BTIG Research started coverage on shares of Definitive Healthcare in a report on Tuesday, September 17th. They set a “buy” rating and a $7.00 price objective on the stock. Stephens started coverage on shares of Definitive Healthcare in a research report on Friday, December 20th. They set an “equal weight” rating and a $5.00 target price on the stock. Finally, Needham & Company LLC restated a “hold” rating on shares of Definitive Healthcare in a research report on Friday, November 8th. Two analysts have rated the stock with a sell rating, six have assigned a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $5.72.

Definitive Healthcare Stock Down 0.2 %

DH stock opened at $4.22 on Monday. The company has a current ratio of 2.49, a quick ratio of 2.49 and a debt-to-equity ratio of 0.33. Definitive Healthcare has a twelve month low of $3.19 and a twelve month high of $10.62. The company’s 50 day moving average is $4.37 and its two-hundred day moving average is $4.53. The stock has a market cap of $487.49 million, a P/E ratio of -1.36, a PEG ratio of 3.14 and a beta of 1.40.

Insider Activity at Definitive Healthcare

In other Definitive Healthcare news, insider William Moschella sold 45,000 shares of the firm’s stock in a transaction on Tuesday, December 3rd. The stock was sold at an average price of $4.70, for a total value of $211,500.00. Following the completion of the sale, the insider now owns 433,830 shares of the company’s stock, valued at approximately $2,039,001. This trade represents a 9.40 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 14.84% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Definitive Healthcare

A number of hedge funds and other institutional investors have recently bought and sold shares of DH. Principal Financial Group Inc. lifted its holdings in Definitive Healthcare by 10.8% in the second quarter. Principal Financial Group Inc. now owns 39,856 shares of the company’s stock valued at $218,000 after acquiring an additional 3,874 shares during the period. Rhumbline Advisers lifted its holdings in Definitive Healthcare by 19.7% in the second quarter. Rhumbline Advisers now owns 83,751 shares of the company’s stock valued at $457,000 after acquiring an additional 13,764 shares during the period. Victory Capital Management Inc. lifted its holdings in Definitive Healthcare by 1.9% in the second quarter. Victory Capital Management Inc. now owns 509,009 shares of the company’s stock valued at $2,779,000 after acquiring an additional 9,316 shares during the period. Massachusetts Financial Services Co. MA lifted its holdings in Definitive Healthcare by 28.3% in the second quarter. Massachusetts Financial Services Co. MA now owns 4,426,420 shares of the company’s stock valued at $24,168,000 after acquiring an additional 976,279 shares during the period. Finally, Renaissance Technologies LLC lifted its holdings in Definitive Healthcare by 50.5% in the second quarter. Renaissance Technologies LLC now owns 28,900 shares of the company’s stock valued at $158,000 after acquiring an additional 9,700 shares during the period. Institutional investors and hedge funds own 98.67% of the company’s stock.

About Definitive Healthcare

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.